Research on SGLT2 Inhibitors Alleviating MASH by Enhancing Ketogenesis to Inhibit CD8+ T Cell Activation Research Background and Problem Positioning Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) has become a global health concern. Its severe stage, Metabolic Dysfunction-Associated Steatohepatitis (MASH), leads to hepatocyte damag...
Novel Subpopulation of Adipose Tissue Macrophages IMAMs and Their Role in Obesity and Metabolic Disorders Background Obesity is an increasingly severe health issue worldwide, often accompanied by a state of chronic low-grade inflammation. This condition is driven by the infiltration and dysfunction of immune cells within adipose tissue and other me...
Cross-Organ Human Fibroblast Atlas Reveals Unique Roles of Different Myofibroblast Subtypes in Immune Regulation Research Background and Motivation Fibroblasts play critical roles in maintaining tissue homeostasis, inflammatory responses, fibrosis, and cancer progression. In recent years, the diversity of fibroblasts in the tumor microenvironment (...
Fibrotic Response Induced by Anti-CSF-1R Treatment Promotes Glioblastoma Recurrence Background Introduction Glioblastoma (GBM) is a highly aggressive and malignant primary tumor of the central nervous system. Although current standard treatments include surgical resection, Temozolomide chemotherapy, and fractionated radiotherapy, the median surviva...
Fusobacterium nucleatum Promotes Anti-PD-1 Therapy in Microsatellite-Stable Colorectal Cancer Background Introduction With the rise of immune checkpoint blockade (ICB) therapy, a new dawn has emerged in cancer treatment. However, despite the approval of PD-1 targeting drugs (e.g., Pembrolizumab) for certain types of colorectal cancer (CRC) patients...
Background and Research Motivation Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive cancer, especially in locally advanced stages. Traditional neoadjuvant chemoradiotherapy (NCRT) is the standard treatment method for this type of cancer. Despite its significant therapeutic effects, local recurrence and distant metastasis rates remai...
Role of Combined Anti-PD-1 and Anti-CTLA-4 Therapy in Melanoma Immune Response Background Immune checkpoint inhibitors have made significant progress in clinical oncology, especially anti-PD-1 (anti-programmed death protein 1) and anti-CTLA-4 (anti-cytotoxic T-lymphocyte-associated antigen 4) therapies, which have been proven to induce long-term re...
Exploration of a Chemotherapy and PD-1 Inhibitor Personalized Stratification Strategy Based on Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Background and Significance of the Study Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths globally. In the treatment of advanced NSCLC, the combination of immune ...
Background Glioblastoma (GBM) is a highly aggressive central nervous system malignancy with very poor prognosis, typically associated with short patient survival. Although significant advancements have been made in tumor treatment technologies and strategies in recent years, traditional radiotherapy and chemotherapy still struggle to achieve satisf...
The Role of Neoadjuvant Chemoradiotherapy Combined or Not Combined with PD-1 Antibody Sintilimab in pMMR Locally Advanced Rectal Cancer: Results of a Randomized Clinical Trial Background and Significance The management of rectal cancer and organ preservation has always been quite challenging, especially in cases of locally advanced rectal cancer (L...